skip to the content

Clinical Trials

Acute Myeloid Leukemia Study

CALGB 10602 "A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia”  (ECOG 1905)

Protocol ID

07.06.034T

Protocol Description

The purpose of this study is to find out what effects, good or bad, one of two treatment programs has on patients and their bone marrow disorder.  One treatment program consists of a new dose and schedule of a drug called Azacitidine, which is approved for the treatment of myelodysplastic syndrome (MDS).  The other treatment program includes the same dose and schedule of Azacitidine in combination with a new, investigational drug known as Entinostat. In this study you will get either Azacitidine alone, or Azacitidine plus Entinostat. Patients will not get both treatment programs.

Eligibility Criteria

Patients with one of the following types of bone marrow disorders: myelodysplastic syndrome (MDS); acute myeloid leukemia (AML), or chronic myelomonocytic leukemia

Primary Investigator(s)

  • Dilip Patel, MD

Contact Information

Dale Janson, RPA-C
(718) 470-4408
djanson@lij.edu

Last Update

March 25, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Blood Disorders:
top
top